THERAPY DOSSIER · th-77aa07b938b4

Sodium hydrosulfide (NaHS)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23092319 ↗2013Reported benefit

Hydrogen sulfide prevents hyperoxia-induced lung injury by downregulating reactive oxygen species formation and angiopoietin-2 release.

MouseOtherC57BL/610 mg/kgGiven with hyperoxia exposure

Model: Hyperoxia induced acute lung injury, 90 vol% oxygen exposure

Sodium hydrosulfide abolished the morphological features of hyperoxic lung injury and significantly reduced angiopoietin-2 expression in vivo.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…